Oppenheimer & CO Inc Mannkind Corp Transaction History

Oppenheimer & CO Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$3.95 - $5.63 $1,185 - $1,689	-300 Reduced 1.52%	19,500 $79,000
Q3 2022 Nov 14, 2022	BUY	$2.99 - $4.35 $8,970 - $13,049	3,000 Added 17.86%	19,800 $61,000
Q2 2022 Aug 08, 2022	SELL	$2.67 - $4.77 $4,005 - $7,154	-1,500 Reduced 8.2%	16,800 $64,000
Q1 2022 May 12, 2022	SELL	$2.62 - $4.45 $6,550 - $11,125	-2,500 Reduced 12.02%	18,300 $67,000
Q4 2021 Feb 02, 2022	SELL	$4.05 - $5.37 $12,150 - $16,110	-3,000 Reduced 12.61%	20,800 $91,000
Q3 2021 Nov 12, 2021	BUY	$3.89 - $5.48 $11,670 - $16,440	3,000 Added 14.42%	23,800 $104,000
Q2 2021 Aug 03, 2021	BUY	$3.61 - $5.45 $75,088 - $113,360	20,800 New	20,800 $113,000
Q4 2020 Feb 11, 2021	SELL	$1.79 - $4.04 $20,943 - $47,268	-11,700 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$1.56 - $2.08 $18,252 - $24,336	11,700 New	11,700 $22,000

248

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.44B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.